At a pair of capital markets days in New York and London, Sandoz has set out expectations for its post-spinoff future – with biosimilars featuring heavily in the company’s growth plans.
Key takeaways:
Sandoz spinoff from Novartis expected in H2 2023
As Sandoz grows ever closer to separating from its parent company Novartis in the second half of this year, the off-patent industry giant has set out its expectations for its post-spinoff future at a pair of capital markets days in New York and London, with biosimilars featuring heavily in its plans.
Setting out expectations for its pipeline to deliver “an additional $3bn in potential net sales over the next five years,...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
